PMID- 36612173
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230111
IS  - 2072-6694 (Print)
IS  - 2072-6694 (Electronic)
IS  - 2072-6694 (Linking)
VI  - 15
IP  - 1
DP  - 2022 Dec 28
TI  - Targeted Therapy for Anaplastic Thyroid Carcinoma: Advances and Management.
LID - 10.3390/cancers15010179 [doi]
LID - 179
AB  - Anaplastic thyroid carcinoma (ATC) is a rare and highly fatal cancer with the 
      worst prognosis of all thyroid carcinoma (TC) histological subtypes and no 
      standard treatment. In recent years, the explosion of investigations on 
      ATC-targeted agents has provided a new treatment strategy for this malignant 
      condition, and a review of these studies is warranted. We conducted a 
      comprehensive literature search for ATC-targeted drug studies and compiled a 
      summary of their efficacy and adverse effects (AEs) to provide new insights. 
      Multiple clinical trials have demonstrated the efficacy and safety of dabrafenib 
      in combination with trametinib for the treatment of ATC, but vemurafenib and NTRK 
      inhibitors showed limited clinical responses. We found that the previously valued 
      therapeutic effect of lenvatinib may be unsatisfactory; combining tyrosine kinase 
      (TK) inhibitors (TKIs) with other agents results in a higher rate of clinical 
      benefit. In addition, specific medications, including RET inhibitors, mTOR 
      inhibitors, CDK4/6 inhibitors, and Combretastatin A4-phosphate (CA4P), offer 
      tremendous therapeutic potential. The AEs reported for all agents are relatively 
      numerous but largely manageable clinically. More clinical trials are expected to 
      further confirm the effectiveness and safety of these targeted drugs for ATC.
FAU - Yuan, Jiaqian
AU  - Yuan J
AUID- ORCID: 0000-0001-6287-5150
AD  - The First Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou 
      310053, China.
FAU - Guo, Yong
AU  - Guo Y
AD  - Department of Medical Oncology, The First Affiliated Hospital of Zhejiang Chinese 
      Medical University, Hangzhou 310001, China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20221228
PL  - Switzerland
TA  - Cancers (Basel)
JT  - Cancers
JID - 101526829
PMC - PMC9818071
OTO - NOTNLM
OT  - BRAF/MEK inhibitors
OT  - anaplastic thyroid carcinoma (ATC)
OT  - targeted therapy
COIS- The authors declare no conflict of interest.
EDAT- 2023/01/09 06:00
MHDA- 2023/01/09 06:01
PMCR- 2022/12/28
CRDT- 2023/01/08 01:07
PHST- 2022/10/31 00:00 [received]
PHST- 2022/12/17 00:00 [revised]
PHST- 2022/12/23 00:00 [accepted]
PHST- 2023/01/08 01:07 [entrez]
PHST- 2023/01/09 06:00 [pubmed]
PHST- 2023/01/09 06:01 [medline]
PHST- 2022/12/28 00:00 [pmc-release]
AID - cancers15010179 [pii]
AID - cancers-15-00179 [pii]
AID - 10.3390/cancers15010179 [doi]
PST - epublish
SO  - Cancers (Basel). 2022 Dec 28;15(1):179. doi: 10.3390/cancers15010179.